Consensus statement on iron overload in myelodysplastic syndromes

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 858-861

  Bennett, John M ^a,b  

^a Myelodysplastic Syndromes Foundation   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; IRON; PLACEBO; TRANSFERRIN;

ANEMIA; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSENSUS; DIAGNOSTIC TEST; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEART OUTPUT; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; ITALY; LEUKEMIA; LIFE EXPECTANCY; LIVER BIOPSY; LIVER LEVEL; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PATIENT MONITORING; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STEM CELL TRANSPLANTATION; SUBSEQUENT QUANTUM INTERFERENCE DEVICE; TISSUE OXYGENATION; TREATMENT DURATION;

CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; FERRITINS; HUMANS; IRON; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 55549139528     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21269     Document Type: Review

References (15)

1. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-1306.
2. Bowen DT, Hellstrom-Lindberg E. Treatment of anemia in myelodysplastic syndromes. In: Bennett JM, editor. Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York: Marcel Dekker; 2002.Chapter 13.
3. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
5. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-4588.
6. Porter J. Pathophysiology of iron overload. Hematol Oncol Clin North Am 2005;Suppl 1:7-12.
7. Piperno A. Classification and diagnosis of iron overload. Haematologica 1998;83:447-455.
8. Gattermann N. Overview of guidelines on iron chelation in patients with myelodysplastic syndrome. Int J Hematol 2008;88:24-29.
9. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008;80:168-176.
10. Di Tucci AA, Matta G, Deplana S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica, in press. Doi:10.3324/hematol. 12759
11. National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members. NCCN practice guidelines: Myelodysplastic syndromes, version 2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed October 29, 2007.
12. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with Thalassemai: Results in Class 3 patients. Blood 1996;87:2082-2088.
13. Majhall NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008;41:997-1003.
14. Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin 2005;Suppl 1:18-25.
15. Chee CE, Steensma DP, Wu W, et al. Niether serum ferritin or the number of red cell transfusions affect survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008;83:611-613.